RGBP Regen Biopharma, Inc.
Distress ·
Regen Biopharma says a delay in its public accountant's review kept it from finishing the Form 10-Q for the period ended June 30, 2026. It says it will file within five calendar days of the due date.
Regen Biopharma issued 77,849,847 common shares between February 4 and February 27, 2026 to settle convertible debt and fees. The company had 212,318,424 shares outstanding on March 3, 2026, and its pipeline has not yet entered a clinical trial.
The notice lists 482 holders of record of common stock and 480 of Series A preferred stock. It relies on Rule 12h-3(b)(1)(ii).
Regen Biopharma, Inc. is a Nevada company that intends to develop regenerative medical applications. It plans to license, develop internally or acquire these applications up to the successful completion of Phase I or Phase II clinical trials, after which it would sell or license them or advance them to Phase III. The company says no clinical trials on its product candidates have commenced. One program, HemaXellarate, is a cellular composition of autologous stromal vascular fraction derived from adipose tissue, which the company believes can regenerate a patient's bone marrow. The company filed an IND with the FDA on February 5, 2013 for a Phase I trial in drug-refractory aplastic anemia, and the FDA later said the clinical hold issues had been addressed. The company has also requested orphan drug designation for HemaXellarate. Other programs include dCellVax, autologous dendritic cells treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase and aimed at breast cancer; tCellVax and DiffronC, which use siRNA against the NR2F6 gene; and DuraCar, CAR-T cells treated with an shRNA targeting NR2F6, which is in pre-clinical testing. The company also holds patents covering NR2F6 modulation and related approaches.
| Product or program | What it is | Stage |
|---|---|---|
| HemaXellarate | Autologous stromal vascular fraction cells for drug-refractory aplastic anemia | Phase I; no clinical trials commenced |
| dCellVax | Autologous dendritic cells treated with an IDO siRNA inhibitor, aimed at breast cancer | no clinical trials commenced |
| tCellVax | Patient immune cells treated with siRNA to inhibit NR2F6 | no clinical trials commenced |
| DiffronC | In vivo siRNA targeting NR2F6 to inhibit cancer growth and activate T cells | no clinical trials commenced |
| DuraCar | CAR-T cells treated with an shRNA targeting NR2F6 | pre-clinical testing |
Our latest story on this, dated Mar 4, 2026: "Regen Biopharma issues 77,849,847 shares to settle convertible debt". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 13, 2026: "Regen Biopharma files late-filing notice for its June 30, 2026 quarterly report". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 4, 2026: "Regen Biopharma issues 77,849,847 shares to settle convertible debt". The story links the filing or release it is based on. Read the story.
Regen Biopharma, Inc. trades under the ticker RGBP on OTC.
Regen Biopharma, Inc. is listed on OTC. Our directory also records these other listings: OTC:RGBPP.
The SEC Central Index Key (CIK) for Regen Biopharma, Inc. is 1589150. Its filings are on SEC EDGAR.
1,675,277,503 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-17.
Our directory records Regen Biopharma, Inc. under United States.
Our directory classifies Regen Biopharma, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Regen Biopharma, Inc. is US75886M3007.
aibio.space lists Regen Biopharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as NV.
Regen Biopharma, Inc. is a Nevada company that intends to develop regenerative medical applications. It plans to license, develop internally or acquire these applications up to the successful completion of Phase I or Phase II clinical trials, after which it would sell or license them or advance them to Phase III.
HemaXellarate: Autologous stromal vascular fraction cells for drug-refractory aplastic anemia Stage: Phase I; no clinical trials commenced.
dCellVax: Autologous dendritic cells treated with an IDO siRNA inhibitor, aimed at breast cancer Stage: no clinical trials commenced.
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a change of independent auditor. SEC Form 8-K (Items 1.01,4.01,8.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). Source
Said earlier financial statements should no longer be relied on. SEC Form 8-K (Items 4.02). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01). Source
Filed to end its SEC reporting. SEC Form 15-15D. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio